Neil Kumar - Feb 16, 2023 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Signature
/s/ Brian C. Stephenson, Attorney-in-Fact
Stock symbol
BBIO
Transactions as of
Feb 16, 2023
Transactions value $
-$871,271
Form type
4
Date filed
2/21/2023, 07:12 PM
Previous filing
Feb 6, 2023
Next filing
Mar 3, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BBIO Common Stock Options Exercise +68.7K +1.43% 4.88M Feb 16, 2023 Direct F1
transaction BBIO Common Stock Tax liability -$302K -23.9K -0.49% $12.64 4.86M Feb 16, 2023 Direct F2
transaction BBIO Common Stock Sale -$569K -44.8K -0.92% $12.70 4.81M Feb 17, 2023 Direct F3, F4
holding BBIO Common Stock 1.37M Feb 16, 2023 See Footnote F5
holding BBIO Common Stock 996K Feb 16, 2023 See Footnote F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BBIO Restricted Stock Units Options Exercise $0 -5.13K -16.67% $0.00 25.6K Feb 16, 2023 Common Stock 5.13K Direct F1, F7
transaction BBIO Restricted Stock Units Options Exercise $0 -2.4K -11.11% $0.00 19.2K Feb 16, 2023 Common Stock 2.4K Direct F1, F8
transaction BBIO Restricted Stock Units Options Exercise $0 -61.2K -20% $0.00 245K Feb 16, 2023 Common Stock 61.2K Direct F1, F9
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2 Represents number of shares of the Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligation in connection with the vesting of 68,705 shares of Common Stock underlying the Reporting Person's RSUs.
F3 This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 5, 2022.
F4 Represents the weighted average sale price of the shares sold from $12.13 to $13.10 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions as reported herein.
F5 The shares are held by Kumar Haldea Revocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
F6 The shares are held by Kumar Haldea Family Irrevocable Trust, of which the Reporting Person is a co-trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that such shares are beneficially owned by the Reporting Person for Section 16 or any other purpose.
F7 The RSUs vest in sixteen quarterly installments after May 16, 2020, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date.
F8 The RSUs vest in sixteen quarterly installments after February 16, 2021, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date, and have no expiration date.
F9 The RSUs vest with respect to 1/8th of the underlying shares on May 16, 2022. Thereafter, 1/8th of the underlying shares shall vest on a quarterly basis, so that all of the underlying shares shall be vested on February 16, 2024, subject to the Reporting Person's continued service to the Issuer or any of its subsidiaries through each vesting date. The RSUs have no expiration date.